biological source
rabbit
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
SP156, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (380R-14), vial of 0.5 mL concentrate (380R-15), bottle of 1.0 mL predilute (380R-17), vial of 1.0 mL concentrate (380R-16), bottle of 7.0 mL predilute (380R-18)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
isotype
IgG
control
hepatocellular carcinoma, normal liver
shipped in
wet ice
storage temp.
2-8°C
visualization
cytoplasmic, nuclear
Gene Information
human ... ARG1(383)
General description
Arginase is a key metalloenzyme of the urea cycle responsible for the hydrolysis of L-arginine to L-ornithine and urea. Two main isoforms exist, arginase-1 and arginase-2, encoded by different genes and with different tissue distributions. The arginase-1 isoform is a cytosolic protein that is produced by normal liver tissue and is typically expressed in hepatocellular carcinoma. Arginase-1 (SP156) is used as an immunohistochemical marker to aid in the identification of hepatocellular carcinoma.
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note
 IVD |  IVD |  IVD |  RUO |
Other Notes
Arginase-1 Positive Control Slides, Product No. 380S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
法规信息
监管及禁止进口产品
此项目有
Benign and malignant tumors of the liver
Linda DF
Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas, 2nd ed., 1291-1325 (2009)
R L Zimmerman et al.
Cancer, 93(4), 288-291 (2001-08-17)
Diagnosing liver tumors by fine-needle aspiration biopsy is safe and accurate. However, there are cases that prove diagnostically difficult. Traditionally, immunostains for alpha-fetoprotein and polyclonal carcinoembryonic antigen have been used to distinguish adenocarcinomas from hepatocellular carcinomas (HCCs). In poorly differentiated
Alexandre Sherlley Casimiro Onofre et al.
Cancer, 111(4), 259-268 (2007-06-15)
Difficulties with cytologic diagnoses on fine-needle aspiration cytology (FNAC) of the liver can be overcome by the application of immunocytochemical panels applied on smears. The aim of the current study was to analyze the performance of a panel of monoclonal
T H Niemann et al.
Cancer, 87(5), 295-298 (1999-10-28)
Fine-needle aspiration biopsy (FNAB) is frequently used to diagnose mass lesions in the liver. Differentiating metastatic adenocarcinoma from primary hepatocellular carcinoma can be difficult. Despite a number of morphologic criteria, there remain occasional cases in which the cytologic features fail
H B el-Serag
Clinics in liver disease, 5(1), 87-107 (2001-02-24)
The epidemiology of hepatocellular carcinoma (HCC) is characterized by marked differences between genders, ethnic groups, and geographic regions. These variations are explained by the nature, frequency, and time of acquisition of the major risk factors for cirrhosis--namely hepatitis B virus
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持